Live Attenuated Vaccines Market

Live Attenuated Vaccines Market is segmented By Type (Viral, Bacteria), By Age Group (Adults, Pediatrics, Geriatrics), By End-User (Hospitals, Clinics, Research Institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

 

Live Attenuated Vaccines Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 10.4% during the forecast period (2022-2029).

Live Attenuated Vaccines Market

Metrics	Details
Market CAGR	10.4%
Segments Covered	By Type, By Age Group, By End-User, and By Region
Report Insights Covered	Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region	Asia Pacific
Largest Market Share	North America

To Get a Free Sample Click here

Live attenuated vaccine (LAV) is prepared from living microorganisms (viruses, bacteria currently available) that have been weakened under laboratory conditions. LAV helps create the immune response, which protects the vaccinated individual from acquiring the same disease. The WHO recommended vaccines such as BCG, polio vaccine, measles, rotavirus and yellow fever are made by attenuation.

Market Dynamics

Live Attenuated Vaccines Market is growing due to several factors such as increasing funding from the government for vaccination programs, rising prevalence of infectious diseases, and growing awareness of infectious diseases.

The rising prevalence of infectious diseases and different initiatives in promoting immunization are expected to drive market growth.

The increasing prevalence of infectious diseases is driving the demand for live attenuated vaccines globally. For instance, according to the World health organization, the number of newly diagnosed and reported cases of TB: from 7.1 million in 2019 to 5.8 million in 2020, far fewer than the approximately 10 million people who developed TB in 2020. Furthermore, government authorities and organizations' increased focus on immunization is fueling the global market growth. For example, the Supplementary immunization campaigns/activities (SIAs) and Periodic Intensification of Routine Immunization (PIRI) by WHO, also, 15 July 2022 – The Government of Indonesia, with support from UNICEF and partners, is continuing to drive catch-up efforts across the country to address a significant backslide in childhood immunization caused by COVID-19. Moreover, from 2000 through 2020, Gavi the Vaccine Alliance is a public-private global health partnership that helped vaccinate more than 888 million children in 77 countries through routine immunization and supported more than 1.19 billion vaccinations through campaigns.

The high developmental cost is hampering the global market growth.

However, limited operating revenue for research and development of novel drugs and high costs associated with the development and stringent regulations are expected to obstruct market growth.

Industry analysis.

The global live attenuated vaccines market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

Segment Analysis

The viral live attenuated vaccines are expected to dominate the market throughout the forecast period (2022-2029).

Viral accounted for the largest market share in 2021 and is estimated to dominate during the forecast period (2022-2029). Some of the viral live attenuated vaccines are oral polio vaccine (OPV), vaccinia (smallpox) vaccine, Adenovirus Oral Vaccine (Military), Yellow Fever Vaccine, Varicella (Chickenpox) Vaccine, Influenza Vaccine (Nasal Spray), FluMist, Rotavirus Vaccine, among others. BCG, or bacilli Calmette-Guerin, is a vaccine for tuberculosis (TB) disease. BCG is used in many countries with a high prevalence of TB to prevent childhood tuberculous meningitis and miliary disease. However, BCG is not generally recommended for use in the United States because of the low risk of infection with Mycobacterium tuberculosis, the variable effectiveness of the vaccine against adult pulmonary TB, and the vaccine’s potential interference with tuberculin skin test reactivity. Furthermore, the increasing clinical research on live viral attenuated vaccines ensures their dominance over the global market; for instance, Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection is estimated to be completed by December 2022 and a Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine which is estimated to be completed by August 2024.

Geographical Analysis

The North American region holds the largest market share of the global Live Attenuated Vaccines market.

North America dominated the global live attenuated vaccines market, accounting for the largest market share in 2021, owing to the rising prevalence of infectious diseases and rising government awareness programs towards vaccination. For instance, according to CDC, A total of 7,163 TB cases were reported in 2020. Also, the Centers for Disease Control and Prevention's (CDC) Advisory Committee for Immunization Practices (ACIP) routinely publishes adult and childhood vaccination recommendations in the United States. The United States has one of the leading healthcare systems globally, and the vaccination coverage, in terms of vaccine inclusion, is at par with the WHO guidelines. Thus, the preventive vaccine market in the region is expected to drive the growth of the live attenuated vaccines market during the forecast period (2022-2029).

Competitive Landscape

The live attenuated vaccines market is highly competitive with the presence of a large number of existing major players and small vendors. Some of the major players in the global live attenuated vaccines market include Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Sanofi, Astellas Pharma, CSL Limited, Serum Institute of India Pvt. Ltd., BioDiem, AstraZeneca, Emergent BioSolutions Inc., Vivaldi Biosciences Inc., among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the live attenuated vaccines market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc.

GlaxoSmithKline plc

Overview:

GSK is a global biopharma company dealing with prescription and nonprescription products. GSK was founded on 27 December 2000 and had headquarters in Brentford, United Kingdom. GSK has 45+ subsidiaries which create its global presence.

Product Portfolio:

 GlaxoSmithKline plc’s product portfolio for Live Attenuated Vaccines has Priorix, Priorix-Tetra, Rotarix and Varilrix.

The global live attenuated vaccines market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Frequently Asked Questions

What is the Projected CAGR value of the Live Attenuated Vaccines Market?

Live Attenuated Vaccines Market is expected to grow at a CAGR of 10.4% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Live Attenuated Vaccines Market during 2022-2029

Which is the fastest growing region in the Live Attenuated Vaccines Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Age-Related Vaccine Adjuvant Market

Anthrax Vaccines Market